Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 1986 Feb;29(2):339-41.

Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.

Abstract

In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.

PMID:
3521480
PMCID:
PMC176405
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center